dipyridamole has been researched along with Hypertension, Pulmonary in 39 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based on the hypothesis that blood platelets contribute to the pathogenesis of hypoxemic pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD), the effect of a prolonged treatment with dipyridamole, a platelet-inhibiting drug, on hypoxemic pulmonary hypertension was evaluated in a double-blind cross-over study." | 9.06 | Effects of dipyridamole on the hypoxemic pulmonary hypertension of patients with chronic obstructive pulmonary disease. ( Berrettini, M; Costantini, V; Nenci, GG; Parise, P; Todisco, T, 1988) |
| "Ginkgo leaf extract and dipyridamole injection (GLED), a kind of Chinese herbal medicine preparation, has been considered as a promising supplementary treatment for chronic cor pulmonale (CCP)." | 9.05 | Ginkgo leaf extract and dipyridamole injection for chronic cor pulmonale: a PRISMA-compliant meta-analysis of randomized controlled trials. ( Guo, Y; Qiu, J; Xu, X; Yang, Y; Yue, H, 2020) |
| "IV dipyridamole prolongs the action of inhaled nitric oxide (NO) in a piglet model of acute pulmonary hypertension." | 7.72 | Intermittent nitric oxide combined with intravenous dipyridamole in a piglet model of acute pulmonary hypertension. ( De Somer, F; De Wolf, D; Foubert, L; Mortier, E; Reyntjens, K; Van Belleghem, Y; Van Nooten, G, 2003) |
| "Inhalation of aerosolized iloprost, a stable prostacyclin analog, has been suggested for treatment of primary and secondary pulmonary hypertension, but demands multiple daily inhalation maneuvers because of the short-term effect of this approach." | 7.71 | Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. ( Ghofrani, HA; Grimminger, F; Krupnik, E; Rose, F; Schermuly, RT; Schudt, C; Seeger, W; Tenor, H; Walmrath, D; Weissmann, N, 2001) |
| "Stable pulmonary hypertension was evoked by continuous infusion of the thromboxane mimetic U46619, resulting in approximate doubling of the pulmonary artery pressure (PAP)." | 5.31 | Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication. ( Enke, B; Forssmann, WG; Ghofrani, HA; Grimminger, F; Schermuly, RT; Seeger, W; Walmrath, D; Weissmann, N, 2001) |
| "Pretreatment with dipyridamole blunted the increase in Ppa and Rp/Rs during repeat hypoxia, keeping Ppa at a subsystemic level and Rp/Rs < 1." | 5.30 | Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. ( Abman, SH; Clarke, WR; Ivy, DD; Kinsella, JP; Wiggins, JW; Ziegler, JW, 1998) |
| "Based on the hypothesis that blood platelets contribute to the pathogenesis of hypoxemic pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD), the effect of a prolonged treatment with dipyridamole, a platelet-inhibiting drug, on hypoxemic pulmonary hypertension was evaluated in a double-blind cross-over study." | 5.06 | Effects of dipyridamole on the hypoxemic pulmonary hypertension of patients with chronic obstructive pulmonary disease. ( Berrettini, M; Costantini, V; Nenci, GG; Parise, P; Todisco, T, 1988) |
| "Ginkgo leaf extract and dipyridamole injection (GLED), a kind of Chinese herbal medicine preparation, has been considered as a promising supplementary treatment for chronic cor pulmonale (CCP)." | 5.05 | Ginkgo leaf extract and dipyridamole injection for chronic cor pulmonale: a PRISMA-compliant meta-analysis of randomized controlled trials. ( Guo, Y; Qiu, J; Xu, X; Yang, Y; Yue, H, 2020) |
| "IV dipyridamole prolongs the action of inhaled nitric oxide (NO) in a piglet model of acute pulmonary hypertension." | 3.72 | Intermittent nitric oxide combined with intravenous dipyridamole in a piglet model of acute pulmonary hypertension. ( De Somer, F; De Wolf, D; Foubert, L; Mortier, E; Reyntjens, K; Van Belleghem, Y; Van Nooten, G, 2003) |
| "Carbon monoxide (CO) has been proposed to attenuate the vasoconstrictor response to local hypoxia that contributes to pulmonary hypertension." | 3.71 | Homogeneous segmental profile of carbon monoxide-mediated pulmonary vasodilation in rats. ( Naik, JS; Walker, BR, 2001) |
| "Inhalation of aerosolized iloprost, a stable prostacyclin analog, has been suggested for treatment of primary and secondary pulmonary hypertension, but demands multiple daily inhalation maneuvers because of the short-term effect of this approach." | 3.71 | Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. ( Ghofrani, HA; Grimminger, F; Krupnik, E; Rose, F; Schermuly, RT; Schudt, C; Seeger, W; Tenor, H; Walmrath, D; Weissmann, N, 2001) |
| "Patients with refractory pulmonary hypertension in whom inhaled nitric oxide alone fails to cause a response may respond to combined therapy of inhaled nitric oxide plus dipyridamole." | 3.69 | Effective control of refractory pulmonary hypertension after cardiac operations. ( Fullerton, DA; Grover, FL; Jaggers, J; McIntyre, RC; Piedalue, F, 1997) |
| " We found that both DIDS and a structurally distinct anion transport blocker, dipyridamole, protected the rabbit IPL from pulmonary hypertension and edema produced by O2 + L-Arg." | 3.69 | Protection of perfused lung from oxidant injury by inhibitors of anion exchange. ( Alper, SL; Huang, YC; Nozik-Grayck, E; Piantadosi, CA; van Adelsberg, J, 1997) |
| "A 33-year-old woman with an atrial septal defect associated with severe pulmonary hypertension underwent suture closure of the defect after assessment of operability by lung biopsy." | 1.32 | Successful weaning from inhaled nitric oxide using dipyridamole. ( Nitta, Y; Saiki, Y; Tabayashi, K; Tsuru, Y, 2003) |
| "1% when administered intravenously at 30 microg/kg to the chronically hypoxic rats and had an apparent oral bioavailability of about 19." | 1.31 | 4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5. ( Adachi, H; Ishibashi, K; Ishihara, H; Kabasawa, Y; Kakiki, M; Kodama, K; Matsukura, M; Miyazaki, K; Nishino, M; Ozaki, H; Takase, Y; Watanabe, N, 2000) |
| "Nitroglycerine infusion was started at 10 mg x hr(-1) shortly after the initiation of DPD." | 1.31 | Treatment of pulmonary hypertension during surgery with nitric oxide and vasodilators. ( Blaise, G; Costachescu, T; Derouin, M; Jiang, ZY, 2000) |
| "Stable pulmonary hypertension was evoked by continuous infusion of the thromboxane mimetic U46619, resulting in approximate doubling of the pulmonary artery pressure (PAP)." | 1.31 | Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication. ( Enke, B; Forssmann, WG; Ghofrani, HA; Grimminger, F; Schermuly, RT; Seeger, W; Walmrath, D; Weissmann, N, 2001) |
| "Pretreatment with dipyridamole did not enhance the pulmonary vasodilation induced by Neb-NP, but did reduce systemic arterial pressure." | 1.30 | Effects of nebulized nitroprusside on pulmonary and systemic hemodynamics during pulmonary hypertension in piglets. ( Bell, A; Hipps, R; Meadow, W; Rudinsky, B, 1998) |
| "Pretreatment with dipyridamole blunted the increase in Ppa and Rp/Rs during repeat hypoxia, keeping Ppa at a subsystemic level and Rp/Rs < 1." | 1.30 | Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. ( Abman, SH; Clarke, WR; Ivy, DD; Kinsella, JP; Wiggins, JW; Ziegler, JW, 1998) |
| "Isosorbide dinitrate was the only drug that elicited any reduction in pulmonary artery pressure; pulmonary vascular resistance decreased modestly." | 1.26 | Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension. ( Bambach, D; Fontana, ME; Hermiller, JB; Huss, P; Leier, CV; Magorien, RD; Thompson, MJ; Unverferth, DV, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (33.33) | 18.7374 |
| 1990's | 10 (25.64) | 18.2507 |
| 2000's | 15 (38.46) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Watanabe, N | 1 |
| Adachi, H | 1 |
| Takase, Y | 1 |
| Ozaki, H | 1 |
| Matsukura, M | 1 |
| Miyazaki, K | 1 |
| Ishibashi, K | 1 |
| Ishihara, H | 1 |
| Kodama, K | 1 |
| Nishino, M | 1 |
| Kakiki, M | 1 |
| Kabasawa, Y | 1 |
| Qiu, J | 1 |
| Guo, Y | 1 |
| Xu, X | 1 |
| Yue, H | 1 |
| Yang, Y | 1 |
| Foubert, L | 2 |
| De Wolf, D | 2 |
| Mareels, K | 1 |
| Van Belleghem, Y | 2 |
| Reyntjens, K | 2 |
| Mortier, E | 2 |
| Van Nooten, G | 2 |
| De Somer, F | 1 |
| Saiki, Y | 1 |
| Nitta, Y | 1 |
| Tsuru, Y | 1 |
| Tabayashi, K | 1 |
| Santini, F | 1 |
| Casali, G | 1 |
| Franchi, G | 1 |
| Auriemma, S | 1 |
| Lusini, M | 1 |
| Barozzi, L | 1 |
| Favaro, A | 1 |
| Messina, A | 1 |
| Mazzucco, A | 1 |
| Main, ML | 1 |
| Ehlgen, A | 1 |
| Coggins, TR | 1 |
| Morris, BA | 1 |
| Lanza, P | 1 |
| Tremblay, TM | 1 |
| Schiller, NB | 1 |
| Goldman, JH | 1 |
| Nenci, GG | 3 |
| Berrettini, M | 2 |
| Todisco, T | 2 |
| Parise, P | 2 |
| Schmoliner, R | 1 |
| Dudczak, R | 1 |
| Kronik, G | 1 |
| Mösslacher, H | 1 |
| Kletter, K | 1 |
| Frischauf, H | 1 |
| Hermiller, JB | 1 |
| Bambach, D | 1 |
| Thompson, MJ | 1 |
| Huss, P | 1 |
| Fontana, ME | 1 |
| Magorien, RD | 1 |
| Unverferth, DV | 1 |
| Leier, CV | 1 |
| Ran, PX | 1 |
| Duan, SF | 1 |
| Schulman, DS | 1 |
| Lazar, JM | 1 |
| Ziady, G | 1 |
| Grandis, DJ | 1 |
| Flores, AR | 1 |
| Orie, JE | 1 |
| Fullerton, DA | 1 |
| Jaggers, J | 1 |
| Piedalue, F | 1 |
| Grover, FL | 1 |
| McIntyre, RC | 1 |
| Nozik-Grayck, E | 1 |
| Piantadosi, CA | 1 |
| van Adelsberg, J | 1 |
| Alper, SL | 1 |
| Huang, YC | 1 |
| Ivy, DD | 3 |
| Kinsella, JP | 3 |
| Ziegler, JW | 4 |
| Abman, SH | 4 |
| Wiggins, JW | 2 |
| Meadow, W | 1 |
| Rudinsky, B | 1 |
| Bell, A | 1 |
| Hipps, R | 1 |
| Hanson, KA | 1 |
| Rybalkin, SD | 1 |
| Miller, JW | 1 |
| Clarke, WR | 2 |
| Arnold, P | 1 |
| Hayden Smith, J | 1 |
| Haynes, S | 1 |
| Hasan, A | 1 |
| Hamilton, JR | 1 |
| Worwag, S | 1 |
| Mulla, H | 1 |
| Luyt, D | 1 |
| Firmin, RK | 1 |
| Thébaud, B | 1 |
| de Lagausie, P | 1 |
| Forgues, D | 1 |
| Aigrain, Y | 1 |
| Mercier, JC | 1 |
| Dinh-Xuan, AT | 1 |
| Jiang, ZY | 1 |
| Costachescu, T | 1 |
| Derouin, M | 1 |
| Blaise, G | 1 |
| Schermuly, RT | 3 |
| Weissmann, N | 3 |
| Enke, B | 1 |
| Ghofrani, HA | 3 |
| Forssmann, WG | 1 |
| Grimminger, F | 3 |
| Seeger, W | 3 |
| Walmrath, D | 3 |
| Roehl, A | 1 |
| Leuchte, H | 1 |
| Naik, JS | 1 |
| Walker, BR | 1 |
| Krupnik, E | 1 |
| Tenor, H | 1 |
| Schudt, C | 1 |
| Rose, F | 1 |
| Buysse, C | 1 |
| Fonteyne, C | 1 |
| Dessy, H | 1 |
| De Laet, MH | 1 |
| Biarent, D | 1 |
| Paleev, NR | 1 |
| Tsar'kova, LN | 1 |
| Chereĭskaia, NK | 1 |
| Baklykova, SN | 1 |
| Keith, IM | 1 |
| Will, JA | 1 |
| Huxtable, RJ | 1 |
| Weir, K | 1 |
| Hainaut, P | 1 |
| Lavenne, E | 1 |
| Magy, JM | 1 |
| Lebacq, EG | 1 |
| Gensini, GF | 1 |
| Rostagno, C | 1 |
| Pezza, A | 1 |
| Fanara, F | 1 |
| Castellani, S | 1 |
| Prisco, D | 1 |
| Rogasi, PG | 1 |
| Boddi, M | 1 |
| Neri Serneri, GG | 1 |
| Costantini, V | 1 |
| Cohen, M | 1 |
| Edwards, WD | 1 |
| Fuster, V | 1 |
| Littler, WA | 1 |
| Redman, CW | 1 |
| Bonnar, J | 1 |
| Beilin, LJ | 1 |
| Lee, Gde J | 1 |
| Swan, H | 1 |
| Meagher, DM | 1 |
| Rosenkrantz, JG | 2 |
| Lynch, FP | 2 |
| Vogel, JH | 2 |
1 review available for dipyridamole and Hypertension, Pulmonary
| Article | Year |
|---|---|
Ginkgo leaf extract and dipyridamole injection for chronic cor pulmonale: a PRISMA-compliant meta-analysis of randomized controlled trials.
Topics: Cardiovascular Diseases; Chronic Disease; Dipyridamole; Drugs, Chinese Herbal; Ginkgo biloba; Humans | 2020 |
3 trials available for dipyridamole and Hypertension, Pulmonary
| Article | Year |
|---|---|
Pulmonary hemodynamic effects of dipyridamole infusion in patients with normal and elevated pulmonary artery systolic pressure receiving PB127.
Topics: Aged; Artifacts; Blood Pressure; Contrast Media; Dipyridamole; Drug Combinations; Echocardiography; | 2006 |
Enhanced plasma beta-thromboglobulin in hypoxemia: effect of dipyridamole.
Topics: Aged; Beta-Globulins; beta-Thromboglobulin; Clinical Trials as Topic; Dipyridamole; Female; Humans; | 1981 |
Effects of dipyridamole on the hypoxemic pulmonary hypertension of patients with chronic obstructive pulmonary disease.
Topics: Aged; Blood Pressure; Dipyridamole; Humans; Hypertension, Pulmonary; Hypoxia; Lung Diseases, Obstruc | 1988 |
35 other studies available for dipyridamole and Hypertension, Pulmonary
| Article | Year |
|---|---|
4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Antihypertensive Agents; Biological Availability; Bloo | 2000 |
Intravenous dipyridamole enhances the effects of inhaled nitric oxide and prevents rebound pulmonary hypertension in piglets.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 3',5'-Cyclic-GMP Phosphodiestera | 2002 |
Intermittent nitric oxide combined with intravenous dipyridamole in a piglet model of acute pulmonary hypertension.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Anesthesia; Animals; Blood Press | 2003 |
Successful weaning from inhaled nitric oxide using dipyridamole.
Topics: Adult; Dipyridamole; Female; Heart Septal Defects, Atrial; Humans; Hypertension, Pulmonary; Nitric O | 2003 |
Hemodynamic effects of inhaled nitric oxide and phosphodiesterase inhibitor (dipyridamole) on secondary pulmonary hypertension following heart valve surgery in adults.
Topics: Administration, Inhalation; Aged; Analysis of Variance; Aortic Valve; Bronchodilator Agents; Cardiac | 2005 |
Platelets, hypoxemia and pulmonary hypertension.
Topics: Blood Platelets; Cyclooxygenase Inhibitors; Dipyridamole; Epoprostenol; Humans; Hypertension, Pulmon | 1984 |
[Biphasic 201thallium scintigraphy after dipyridamole in mitral valve diseases (author's transl)].
Topics: Adult; Aged; Blood Pressure; Dipyridamole; Female; Heart; Humans; Hypertension, Pulmonary; Male; Mid | 1980 |
Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension.
Topics: Adolescent; Adult; Aspirin; Diazoxide; Dipyridamole; Female; Hemodynamics; Humans; Hydralazine; Hype | 1982 |
[The effects of persantine on pulmonary arterial pressure of rats exposed to hypoxia].
Topics: Animals; Blood Pressure; Dipyridamole; Hypertension, Pulmonary; Hypoxia; Male; Rats; Rats, Sprague-D | 1993 |
Right ventricular thallium-201 kinetics in pulmonary hypertension: relation to right ventricular size and function.
Topics: Adult; Dipyridamole; Female; Heart; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; | 1993 |
Effective control of refractory pulmonary hypertension after cardiac operations.
Topics: Aged; Blood Pressure; Dipyridamole; Drug Combinations; Heart Valve Diseases; Hemodynamics; Humans; H | 1997 |
Protection of perfused lung from oxidant injury by inhibitors of anion exchange.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Animals; Antiporters; Arginine; Blotting, Western; | 1997 |
Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Administration, Inhalation; Adolescent; Child, Preschool; Dipyr | 1998 |
Hemodynamic effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension.
Topics: Administration, Inhalation; Child; Dipyridamole; Heart Defects, Congenital; Hemodynamics; Humans; Hy | 1998 |
Effects of nebulized nitroprusside on pulmonary and systemic hemodynamics during pulmonary hypertension in piglets.
Topics: Administration, Inhalation; Aerosols; Animals; Blood Gas Analysis; Cyclic GMP; Dipyridamole; Hemodyn | 1998 |
Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Animals, Newborn; Blood Pressure; Chronic Disease; Cyc | 1998 |
Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension.
Topics: Administration, Inhalation; Adolescent; Adult; Aorta; Blood Pressure; Bronchodilator Agents; Cardiac | 1998 |
Use of dipyridamole for pulmonary hypertension following repair of total anomalous pulmonary venous drainage.
Topics: Dipyridamole; Humans; Hypertension, Pulmonary; Infant, Newborn; Male; Postoperative Complications; P | 2000 |
Dipyridamole in the treatment of a neonate with persistent pulmonary hypertension.
Topics: Dipyridamole; Extracorporeal Membrane Oxygenation; Humans; Hypertension, Pulmonary; Infant, Newborn; | 2000 |
ET(A)-receptor blockade and ET(B)-receptor stimulation in experimental congenital diaphragmatic hernia.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Cyclic GMP; Dipyridamole; Disease Models, Animal; E | 2000 |
Treatment of pulmonary hypertension during surgery with nitric oxide and vasodilators.
Topics: Administration, Inhalation; Colectomy; Cyclic GMP; Dipyridamole; Female; Hemodynamics; Humans; Hyper | 2000 |
Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Administration, Inhalation; Anim | 2001 |
Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Administration, Inhalation; Anim | 2001 |
Homogeneous segmental profile of carbon monoxide-mediated pulmonary vasodilation in rats.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Carbon Monoxide; Cyclic | 2001 |
Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aerosols; Animals; Dipyridamole; | 2001 |
The use of dipyridamole to wean from inhaled nitric oxide in congenital diaphragmatic hernia.
Topics: Dipyridamole; Extracorporeal Membrane Oxygenation; Hernia, Diaphragmatic; Hernias, Diaphragmatic, Co | 2001 |
[Treatment of patients with chronic obstructive bronchitis and pulmonary hypertension during ambulatory care].
Topics: Adrenergic beta-Agonists; Bronchitis; Chronic Disease; Climate; Delayed-Action Preparations; Dipyrid | 1990 |
Anti-platelet agents reduce morphological changes of chronic hypoxic pulmonary hypertension.
Topics: Animals; Dipyridamole; Flunarizine; Heart; Heart Ventricles; Hypertension, Pulmonary; Hypoxia; Male; | 1987 |
Circulating lupus type anticoagulant and pulmonary hypertension associated with mixed connective tissue disease.
Topics: Adult; Arterial Occlusive Diseases; Aspirin; Blood Coagulation Factors; Dipyridamole; Female; Hand; | 1986 |
Effects of dipyridamole infusion on local platelet aggregation and local formation of thromboxane A2 in patients with pulmonary hypertension.
Topics: beta-Thromboglobulin; Dipyridamole; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Obstruct | 1985 |
Regression in thromboembolic type of primary pulmonary hypertension during 2 1/2 years of antithrombotic therapy.
Topics: Cardiac Catheterization; Dipyridamole; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmon | 1986 |
Reduced pulmonary arterial compliance in hypertensive pregnancy.
Topics: Adult; Blood Pressure; Capillaries; Cardiac Output; Dipyridamole; Elasticity; Electrocardiography; F | 1973 |
Total body bypass in miniature pigs. Postperfusion pulmonary hypertension.
Topics: Acidosis; Anesthesia, Inhalation; Animals; Blood Group Incompatibility; Blood Pressure; Capillary Pe | 1971 |
Hypoxic pulmonary hypertension: its modification by dipyridamole.
Topics: Animals; Blood Pressure; Cardiac Catheterization; Cardiac Output; Dipyridamole; Hemodynamics; Hypert | 1972 |
Pulmonary hypertension: treatment by drugs which modify intravascular aggregation.
Topics: Animals; Blood Platelets; Dipyridamole; Hypertension, Pulmonary; Hypoxia; Swine | 1969 |